Unique ID issued by UMIN | UMIN000038653 |
---|---|
Receipt number | R000044046 |
Scientific Title | The Usefulness of a Cross-border Tuberculosis Patient Referral Mechanism in Asia |
Date of disclosure of the study information | 2019/11/21 |
Last modified on | 2023/12/06 10:57:48 |
The Usefulness of a Cross-border Tuberculosis Patient Referral Mechanism in Asia
The Usefulness of a Cross-border Tuberculosis Patient Referral Mechanism in Asia
The Usefulness of a Cross-border Tuberculosis Patient Referral Mechanism in Asia
Bridge TB Care
Japan | Asia(except Japan) |
tuberculosis
Infectious disease |
Others
NO
The aim of the study is to establish a cross-border TB patient referral mechanism in Asia and to evaluate its effectiveness through the status of the TB patients referred on the access to health facilities as well as on the TB treatment outcomes.
Efficacy
TB treatment success rate (%) after return to the original home country
TB patient access rate (%) after return to the orignal home country
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Behavior,custom |
A cross-border TB patient Referral Mechanism:
i) The pathway of the mechanism in Japan
a) To make the mechanism publicly known through the home page of the Research Institute of Tuberculosis (RIT), JATA, Tokyo, Japan.
b) A public health center / a medical institution in Japan initially coordinates with the RIT through phone/fax/e-mail, followed by sending a TB patient referral form and an informed consent form to the RIT.
c) The RIT in Japan contacts with a relevant NTP staff at the country where the TB patient returns, asking to search a suitable health facility that the TB patient should access after he/she goes back, and to monitor his/her treatment status.
d) The RIT in Japan communicate with the public health center / the medical institution in Japan to provide the treatment status of the TB patient referred to his/her home country.
ii) The pathway of the mechanism in the TB patient home country:
a) The NTP concerned asks relevant agencies such as regional / provincial / city health office to search a suitable health center / medical institution that the TB patient should access.
b) The NTP concerned collect information about the TB patient treatment status monthly or bi-monthly through the relevant agencies, then forward the information to the RIT via e-mail.
18 | years-old | <= |
Not applicable |
Male and Female
All of the TB patients including the latent TB infection patients who were born in either of the four countries, i.e., China, Viet Nam, the Philippines, South Korea, and Myanmar, are diagnosed from April 2019 till March 2012 in Japan, are willing to return back to their home country during the treatment, provide the informed consent form, and are 18 years old and above are eligible to be involved in the study.
All TB patients who do not fall in any of the criteria above.
100
1st name | OHKADO |
Middle name | |
Last name | AKIHIRO |
Research Institute of Tuberculosis (RIT), Japan Anti-Tuberculosis Association (JATA)
Department of Epidemiology and Clinical Research
204-8533
Matsuyama 3-1-24, Kiyose, Tokyo
042-493-3090
rit.epi.9305@jata.or.jp
1st name | OHKADO |
Middle name | |
Last name | AKIHIRO |
Research Institute of Tuberculosis (RIT), Japan Anti-Tuberculosis Association (JATA)
Department of Epidemiology and Clinical Research
204-8533
Matsuyama 3-1-24, Kiyose, Tokyo
042-493-3090
rit.epi.9305@jata.or.jp
Research Institute of Tuberculosis (RIT), Japan Anti-Tuberculosis Association (JATA)
the Japan Society for the Promotion of Science (JSPS)
Japanese Governmental office
Research Institute of Tuberculosis (RIT), Japan Anti-Tuberculosis Association (JATA)
Matsuyama 3-1-24, Kiyose, Tokyo
042-493-5711
kenkyushien@jata.or.jp
NO
2019 | Year | 11 | Month | 21 | Day |
Unpublished
135
83.0% (112 / 135) were confirmed to have accessed a medical facility in the destination country.
TB Treatment success rate among 102 cases whose expected treatment end date was due by July 31, 2023: 85.3% (87 / 102).
Treatment outcome confirmation methods among those whose treatment outcomes were confirmed (87 cases)
-By official confirmation (i.e., by the National TB Control programme, health center, private or public medical facilities): 49 cases (56.3%)
2023 | Year | 12 | Month | 06 | Day |
No longer recruiting
2019 | Year | 09 | Month | 03 | Day |
2019 | Year | 09 | Month | 09 | Day |
2019 | Year | 09 | Month | 09 | Day |
2024 | Year | 03 | Month | 31 | Day |
2024 | Year | 03 | Month | 31 | Day |
2024 | Year | 03 | Month | 31 | Day |
2024 | Year | 08 | Month | 31 | Day |
2019 | Year | 11 | Month | 21 | Day |
2023 | Year | 12 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044046
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |